Skip to content
Screener

Castle Biosciences CSTL EV / EBITDA

EV / EBITDA at other companies

Labcorp Holdings logo
Labcorp HoldingsLH
13.3×-1.4×
Veracyte logo
VeracyteVCYT
23.6×-22.7×
GeneDx Holdings logo
GeneDx HoldingsWGS
310.1×—
Quest Diagnostics logo
Quest DiagnosticsDGX
13.2×+0.3×

Other financials

Income statement

See full
Revenue$83.7M-4.9%
Gross profit$63.1M-11.8%
Operating income-$18.4M+34.1%
Net income-$14.5M+43.8%
EPS (diluted)-$0.49+45.6%

Balance sheet

See full
Cash & equivalents$63.8M-28.9%
Total debt$36.7M+42.1%
Total equity$461.4M+4.8%
Total assets$547.8M+9.2%

Cash flow

See full
Operating cash flow-$22.1M-267%
CapEx$12.5M+163%
Free cash flow-$34.6M-221%

Valuation

See full
Market cap$855.39M+93.4%
Enterprise value$828.35M+108%
P/S2.5×+1.2×

Profitability

See full
Gross margin77.9%-4.1pp
Operating margin-9.8%-30.8pp
Net margin-3.8%-10.2pp
FCF margin1.3%-10.7pp

Returns & leverage

See full
Return on equity-2.8%-10.6pp
Debt / equity0.1×0.0×
Current ratio6.7×-2.6×

Where this comes from

Calculated from Castle Biosciences’s reported figures.

enterprise value/ebitda=78.2×

Based on the most recent quarter.

The source filing: Castle Biosciences’s 10-Q, filed November 3, 2025. Open the filing →

Filed
Nov 3, 2025
Fiscal quarter
Q3 FY2025
Calendar quarter
Q3 2025
Accession
0001628280-25-048254

FAQ

What is Castle Biosciences's EV / EBITDA?
Castle Biosciences (CSTL) reported EV / EBITDA of 78.2× in Q3 2025.
How has Castle Biosciences's EV / EBITDA changed year-over-year?
Castle Biosciences's EV / EBITDA increased by 34.3% year-over-year, from 58.2× to 78.2×.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.

Ask your AI about Castle Biosciences's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude